Suppr超能文献

综合分析揭示肺腺癌细胞衰老的预后和免疫原性特征。

Comprehensive Analysis Uncovers Prognostic and Immunogenic Characteristics of Cellular Senescence for Lung Adenocarcinoma.

作者信息

Lin Weihao, Wang Xin, Wang Zhen, Shao Fei, Yang Yannan, Cao Zheng, Feng Xiaoli, Gao Yibo, He Jie

机构信息

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Front Cell Dev Biol. 2021 Nov 16;9:780461. doi: 10.3389/fcell.2021.780461. eCollection 2021.

Abstract

Cellular senescence plays a crucial role in tumorigenesis, development and immune modulation in cancers. However, to date, a robust and reliable cellular senescence-related signature and its value in clinical outcomes and immunotherapy response remain unexplored in lung adenocarcinoma (LUAD) patients. Through exploring the expression profiles of 278 cellular senescence-related genes in 936 LUAD patients, a cellular senescence-related signature (SRS) was constructed and validated as an independent prognostic predictor for LUAD patients. Notably, patients with high SRS scores exhibited upregulation of senescence-associated secretory phenotype (SASP) and an immunosuppressive phenotype. Further analysis showed that SRS combined with immune checkpoint expression or TMB served as a good predictor for patients' clinical outcomes, and patients with low SRS scores might benefit from immunotherapy. Collectively, our findings demonstrated that SRS involved in the regulation of the tumor immune microenvironment through SASP was a robust biomarker for the immunotherapeutic response and prognosis in LUAD.

摘要

细胞衰老在癌症的肿瘤发生、发展和免疫调节中起着至关重要的作用。然而,迄今为止,在肺腺癌(LUAD)患者中,尚未探索出强大且可靠的细胞衰老相关特征及其在临床结局和免疫治疗反应中的价值。通过探索936例LUAD患者中278个细胞衰老相关基因的表达谱,构建了一种细胞衰老相关特征(SRS),并验证其为LUAD患者的独立预后预测指标。值得注意的是,SRS评分高的患者表现出衰老相关分泌表型(SASP)和免疫抑制表型的上调。进一步分析表明,SRS与免疫检查点表达或肿瘤突变负荷(TMB)相结合可作为患者临床结局的良好预测指标,且SRS评分低的患者可能从免疫治疗中获益。总体而言,我们的研究结果表明,通过SASP参与肿瘤免疫微环境调节的SRS是LUAD免疫治疗反应和预后的强大生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa70/8636167/b218a0148369/fcell-09-780461-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验